Wound Management News

A number of interventions and therapeutic combinations are available to treat scarring and dyschromias in individuals with Fitzpatrick skin type IV to VI, or “skin of color,” according to a study.

MIAMI BEACH, Fla. — Although they should never be injected, exosomes could change the way dermatologists heal the skin, according to a speaker at South Beach Symposium.

Patients with keloids and hypertrophic scarring were at a higher risk of developing atopic eczema, in addition to other comorbidities, across three major ethnic groups, according to a study.

Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with the general population, according to a cohort study.

Patients with intermediate junctional epidermolysis bullosa are at risk for kidney-urinary tract manifestations, according to a study.

Nonabsorbable sutures or tissue adhesives used in combination with surgical strips and liquid adhesives are safe and effective means to minimizing hyperpigmentation in skin of color following Mohs micrographic surgery, according to a study.

Patients with dystrophic epidermolysis bullosa had positive phase 3 results with Vyjuvek treatment, Krystal Biotech announced in a press release.

The FDA has denied a New Drug Application for oleogel-S10 for the treatment of the cutaneous manifestations of dystrophic and junctional epidermolysis bullosa, Amryt Pharma announced in a press release.

The addition of a tumor necrosis factor inhibitor to steroid therapy reduced acute stage disease duration and hospital stay in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, according to a study.

Enrollment in a trial to evaluate the Recell system for soft-tissue reconstruction has been completed, according to a press release from Avita.